Previous 10 | Next 10 |
Seth Klarman’s 13F portfolio value decreased from $12.56B to $12.33B this quarter. Baupost Group increased Micron Technology and Facebook while dropping Fox Corp. The portfolio continues to be heavily concentrated with the top three positions accounting for ~32% of the 13F ...
The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Atara Biotherapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Atara Biotherapeutics, Inc. (ATRA) Q2 2021 Earnings Conference Call August 9, 2021 16:30 ET Company Participants Eric Hyllengren - Vice President of Investor Relations & Finance Pascal Touchon - President & Chief Executive Officer Jakob Dupont - Executive Vice President and Global Hea...
Image source: The Motley Fool. Atara Biotherapeutics, inc (NASDAQ: ATRA) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcrip...
Progress with FDA on evaluating tab-cel ® product comparability and new robust Phase 3 ALLELE study data Recent positive milestones with EMA provide clear path for EU Marketing Authorization Application submission in November 2021 Important new ATA188 magnetiz...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Dir...
Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, toda...
Initiative aims to advance timely access to innovative therapies for those living with rare conditions Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies f...
ATRA will have an approval next year in a rare disease. Its major deal with Bayer validates its earliest stage programs. Its mid-stage MS program also produced strong data. For further details see: Atara Biotherapeutics: Upcoming Catalysts And Validated Pipeline
All patients with a complete response (CR) or a partial response (PR) to tab-cel ® alive at one year Overall tab-cel ® survival benefit demonstrated across previous treatment subgroups Phase 2 results validate potential life-saving benefit of treatmen...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...